(Q39092574)

English

Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma

scientific article published on 24 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma (English)

1 reference

Europe PubMed Central

9 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Tsutomu Nakazawa

1

1 reference

Europe PubMed Central

9 September 2017

Mitsutoshi Nakamura

2

1 reference

Europe PubMed Central

9 September 2017

Young Soo Park

3

1 reference

Europe PubMed Central

9 September 2017

Yasushi Motoyama

4

1 reference

Europe PubMed Central

9 September 2017

Yasuo Hironaka

5

1 reference

Europe PubMed Central

9 September 2017

Fumihiko Nishimura

6

1 reference

Europe PubMed Central

9 September 2017

Ichiro Nakagawa

7

1 reference

Europe PubMed Central

9 September 2017

Shuichi Yamada

8

1 reference

Europe PubMed Central

9 September 2017

Ryosuke Matsuda

9

1 reference

Europe PubMed Central

9 September 2017

Kentaro Tamura

10

1 reference

Europe PubMed Central

9 September 2017

Tadashi Sugimoto

11

1 reference

Europe PubMed Central

9 September 2017

Yasuhiro Takeshima

12

1 reference

Europe PubMed Central

9 September 2017

Akiko Marutani

13

1 reference

Europe PubMed Central

9 September 2017

Takahiro Tsujimura

14

1 reference

Europe PubMed Central

9 September 2017

Noriko Ouji

15

1 reference

Europe PubMed Central

9 September 2017

Yukiteru Ouji

16

1 reference

Europe PubMed Central

9 September 2017

Masahide Yoshikawa

17

1 reference

Europe PubMed Central

9 September 2017

Hiroyuki Nakase

18

1 reference

Europe PubMed Central

9 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

24 September 2013

1 reference

Europe PubMed Central

9 September 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

9 September 2017

116

1 reference

Europe PubMed Central

9 September 2017

1

1 reference

Europe PubMed Central

9 September 2017

31-39

1 reference

Europe PubMed Central

9 September 2017

https://scigraph.springernature.com/pub.10.1007/s11060-013-1258-4

0 references

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

[gamma][delta] cells: a right time and a right place for a conserved third way of protection

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Gamma/delta cells.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Perspectives of gammadelta T cells in tumor immunology

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

V gamma 9V delta 2 T cell response to colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Charting the course across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Quantitative morphology of human glioblastoma multiforme microvessels: structural basis of blood-brain barrier defect.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1258-4

21 January 2018

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overview of cellular immunotherapy for patients with glioblastoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel immunotherapeutic approaches to glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gamma delta T cell receptor analysis supports a role for HSP 70 selection of lymphocytes in multiple sclerosis lesions

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-013-1258-4

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39092574&oldid=2120940357"